LONDON, June 12 -- The government of the United Kingdom issued the following news:

The Medicines and Healthcare products Regulatory Agency (MHRA) hastoday, 12 June 2026, approved a newlower doseversion of the adrenaline (epinephrine) nasal spray, EURneffy, for the emergency treatment ofserious allergic reactions(anaphylaxis)in childrenaged four years and over.

This approval means younger children are eligible for a needle-free treatmentoptionfor the first timein the UK.

The1 mgdosenasal spray isindicatedfor children aged 4 years and over who weigh between 15 kgand 30 kg. Thisextendsaccess beyond the previously authorised 2 mg product, which is intended foradults andchildren10 years and aboveweighing 30 kg or more.

Adrenaline isawell-establishedtreatment forseriousallergicreactions and is intended for immediate self-administrationat the first signs of anaphylaxis,before emergency medical help arrives.

The nasal spraydeliversadose intothenostril andissuitable for use even if the nose iscongested.As with adrenaline auto-injectors, two doses(sprays)mustalways be carriedin case a second dose is needed before the ambulance arrives.'999'must be dialledimmediatelyafter a dose has been given.

The new 1 mg doseprovidesan alternativefor younger patients, who until now have relied on injectable adrenaline devices.

As with any medicine, the MHRA will keep the safety and effectiveness of the adrenaline nasal spray under close review.    

Notes to editors  

*

Thenew marketingauthorisationwasgranted on12June 2026toALK-Abelló A/S

*

More information can be found in the Summary of Product Characteristics and Patient Information leaflets which will be published on theMHRA Products websitewithin 7 days of approval.  

*

The Medicines and Healthcare products Regulatory Agency (MHRA)is responsible forregulating all medicines and medical devices in the UK by ensuring they work and are acceptably safe.  All our work is underpinned by robust and fact-based judgements to ensure that the benefits justify any risks.  

*

The MHRA is an executive agency of the Department of Health and Social Care.  

*

For media enquiries, please contact thenewscentre@mhra.gov.uk, or call on 020 3080 7651.

Disclaimer: Curated by HT Syndication.